Overview

A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment

Status:
Completed

Trial end date:
2007-09-01

Target enrollment:

Participant gender:

Summary

This is a multi-center, open-label study of 28 weeks duration in subjects with Mild Cognitive Impairment who have completed the double-blind study (E2020-A001-412).

Phase:

Phase 4

Details

Lead Sponsor:

Eisai Inc.

Treatments:

Donepezil